Corporate & Investor Presentation
Patient engagement drives 87% adherence to PAP therapy
Cumulative percentage of patients
1.0
0.9
0.8
NO
0.7
0.6
0.5
0.4
0.3
0.2
0.1
-AirView only (N=85,358) ―myAir (N=42,679)
0.0
0
10
20
30
40
50
60
70
80
90
About the clinical study
.
Largest clinical study 1 to date assessing the
impact of adding the myAir patient engagement
tool for PAP patients already using AirView
Resulted in more than 137 million nights of data
• Patients in both groups were treated with PAP
therapy over the 90 days.
Personalized engagement benefits everyone
•
Significantly improves adherence
• Can be achieved with minimal burden on providers.
Days to achieve CMS adherence
Patients who use myAir and AirView improved adherence by 17% over those who only use AirView
1.
Malhotra et al CHEST 2018
46 2022 ResMed | Corporate & Investor Presentation - updated 27JAN22
ResMedView entire presentation